Artificial intelligence enables the processing of datasets of unprecedented size and complexity to identify and prioritize novel drug candidates. We look for companies that can combine novel computational platforms with strong drug development expertise to develop potential breakthrough medicines.
Recursion Pharmaceuticals has developed a high throughput platform based on AI computer vision and coupled it with deep disease biology and chemistry to build a deep and data-rich pipeline. The company has initiated four clinical programs so far from a pipeline of dozens of pre-clinical programs. We invested in the Series B in 2017, and Recursion went public in 2021.
Greg is a partner at Menlo Ventures, where he invests in teams trying to solve major problems in life science and healthcare, with a special interest in novel therapeutic platforms, digital health, and transformative technologies. Since joining in 2017, Greg has led Menlo investments including Cartwheel, Clear Labs, Curie, Delfi,…
As a principal at Menlo Ventures, Johnny invests in biotech and life science companies with a focus on novel therapeutics and new technologies for improving medical outcomes. He has firsthand experience working at the bench on engineering new tools for the clinic. While completing his Ph.D., Johnny helped develop gene…
